SCHEMBL12828564

SCHEMBL12828564

CCOC(=O)CNC(=O)c1c(O)cc(CCc2ccccc2)n2ncnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 8/20 0.50
HPGD P15428 3/20 0.44
ALDH1A1 P00352 5/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PPID Q08752 1/20 0.42
BBOX1 O75936 1/20 0.41
ASPH Q12797 1/20 0.41
KDM8 Q8N371 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
POLB P06746 1/20 0.40
HSD17B10 Q99714 3/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.38
ATM Q13315 1/20 0.37
USP2 O75604 1/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enarodustat SCHEMBL1481440 0.87 EGLN1 (0.64) EGLN1BBOX1ASPHKDM8
SCHEMBL12828314 0.86 ALDH1A1 (0.40) EGLN1HPGDALDH1A1TP53L3MBTL1
Enarodustat SCHEMBL1481939 0.86 EGLN1 (0.65) EGLN1BBOX1ASPHKDM8
SCHEMBL8527866 0.85 EGLN1 (0.47) EGLN1HPGDALDH1A1TP53KDM4E
SCHEMBL1483208 0.81 EGLN1 (0.59) EGLN1BBOX1ASPHKDM8
SCHEMBL8517546 0.81 HPGD (0.41) EGLN1HPGDALDH1A1TP53KDM4E
SCHEMBL8529005 0.81 EGLN1 (0.47) EGLN1HPGDBBOX1ASPHKDM8
SCHEMBL38660583 0.80 EGLN1 (0.46) EGLN1KDM4EBBOX1ASPHKDM8
SCHEMBL30812491 0.79 EGLN1 (0.49) EGLN1BBOX1ASPHKDM8LMNA
SCHEMBL8523240 0.79 EGLN1 (0.46) EGLN1ALDH1A1BBOX1ASPHKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
EP-2455381-B9 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-10-22 EP disclosed
EP-2455381-B1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-05-28 EP disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 EGLN1 8/4885HPGD 220/4885ALDH1A1 309/4885
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 EGLN1 8/4885HPGD 220/4885ALDH1A1 309/4885
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 EGLN1 8/4885HPGD 220/4885ALDH1A1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.